CD38 and plasma cell myeloma: For example, in a study using CD38- or CD138-targeted liposomal NPs in myeloma models, the targeted particles demonstrated significantly higher in vivo tumor accumulation and cellular uptake compared to non-targeted forms, thereby validating NPs delivery within the bone marrow microenvironment [79,108].